Vascular endothelial growth factor variants

Details Vascular endothelial growth factor variants Vascular endothelial growth factor variants

2005-05-03

2005-05-03

Andres, Janet (Department: 1646)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S350000, C435S455000

Reexamination Certificate

active

06887848

ABSTRACT:
The invention is directed to a method of enhancing the biological activity of vascular endothelial growth factors (VEGF). The invention further concerns certain VEGF variants having enhanced biological activity, methods and means for preparing these variants, and pharmaceutical compositions comprising them. In a further aspect, the invention concerns methods of treatment using, and articles of manufacture containing such VEGF variants.

REFERENCES:
patent: 3187748 (1965-06-01), Mitchell et al.
patent: 3565070 (1971-02-01), Hanson et al.
patent: 3658059 (1972-04-01), Steil
patent: 3814297 (1974-06-01), Warren
patent: 3826413 (1974-07-01), Warren
patent: 4527769 (1985-07-01), Stogner et al.
patent: 4592348 (1986-06-01), Waters, IV et al.
patent: 4648393 (1987-03-01), Landis et al.
patent: 4677975 (1987-07-01), Edgar et al.
patent: 4790305 (1988-12-01), Zoltan et al.
patent: 4803978 (1989-02-01), Johnson, IV et al.
patent: 4812405 (1989-03-01), Lair et al.
patent: 4818700 (1989-04-01), Cregg et al.
patent: 4896832 (1990-01-01), Howlett
patent: 4926852 (1990-05-01), Zoltan et al.
patent: 4943529 (1990-07-01), Van Den Berg et al.
patent: 4952496 (1990-08-01), Studier et al.
patent: 4992901 (1991-02-01), Keel et al.
patent: 5194596 (1993-03-01), Tischer et al.
patent: 5219739 (1993-06-01), Tischer et al.
patent: 5240848 (1993-08-01), Keck et al.
patent: 5244460 (1993-09-01), Unger et al.
patent: 5332671 (1994-07-01), Ferrara et al.
patent: 5378613 (1995-01-01), Belagaje
patent: 5595888 (1997-01-01), Gray et al.
patent: 5648233 (1997-07-01), Yamaguchi et al.
patent: 5665600 (1997-09-01), Hagenson et al.
patent: 5693489 (1997-12-01), Studier et al.
patent: 5705362 (1998-01-01), Bonekamp et al.
patent: 5783416 (1998-07-01), Thim et al.
patent: 5785965 (1998-07-01), Pratt et al.
patent: 5935820 (1999-08-01), Hu et al.
patent: 6013780 (2000-01-01), Neufeld et al.
patent: 6475796 (2002-11-01), Pollitt et al.
patent: 0370989 (1989-11-01), None
patent: 0484401 (1990-07-01), None
patent: B0484401 (1991-02-01), None
patent: WO 9312142 (1993-06-01), None
patent: WO 9606641 (1996-03-01), None
patent: WO 97 08313 (1997-03-01), None
patent: WO9810071 (1998-03-01), None
patent: WO 9816551 (1998-04-01), None
patent: WO982411 (1998-06-01), None
patent: WO 9824811 (1998-06-01), None
Khan et al. Exp. Opin. Pharmacother. 2003, vol. 4(2), pp. 219-226.*
Belagaje et al. (1997).Protein Sci6(9):1953-62.
Ben-Bassatt (1991).Bioprocess Tech12:147-159.
Breier et al. (1992).Development114:521-532.
Christinger et al. (1996).Proteins: Structure, Function,&Genetics26:353-357.
Claffey et al. 1995).Biochimica et Biophysica Acta1246:1-9.
Dalboge et al. (1987)Bio/Tech5:161-164.
Ferrara et al. (1991).J Cell Biochem47(3):211-218.
Patel et al. (1999).Human Gene Therapy10(8).
Poetgens et al. (1994).J Bio Chem269(52):32879-32885.
International Search Report mailed on Oct 18, 2000 for PCT patent application No. PCT/US00/13536 filed on May 18, 2000, 4 pages.
Achen et al. “Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2(Flk1) and VEGF receptor 3(Flt4)”Proc. Natl. Aca. Sci.95:548-553 (1998).
Altschul et al., “Gapped BLAST and PSI-BLAST: a new generation of protein database programs”,Nucleic Acids Res., 25:3389-3402 (1997).
Ausubel et al., “Current Protocols in Molecular Biology” eds. (1987).
Beach and Nurse, “High-frequency transformation of the fission yeastSchizosaccharomyces pombe” Nature 290:140 (1981).
C. Anthony, “The Biochemistry of Metholotrophis”Department of Biochemistry University of Southampton,England, 269 (1982).
Cohen et al., “High levels of Biologically Active Vascular Endothelial Growth Factor (VEGF) are Produced by the Baculovirus Expression System”,Growth Factors7:131-138 (1993).
Cohen et al., “VEGF121, a Vascular Endothelial Growth Factor (VEGF) Isoform Lacking Heparin Biding Ability, Requires Cell-Surface Heparin Sulfates for Efficient Binding to VEGF Receptors of Human Melanoma Cells”,J. Biol. Chem.270:11322-11326 (1995).
Conn et al., “Purification of glycoprotein vascular endothelial cell mitogen from a rat glioma-derived cell line”,PNAS USA,87:1323-1327 (1990)
Connolly et al., “Human Vascular Permeability Factor”J. Biol Chem. 264:20017-20024 (1989).
Connolly et al., “Tumor Vascular Permeability Factor Stimulates Endothelial Cell Growth and Angiogenesis”,J. Clin. Invest. 84:1470-1478 (1989).
Cregg et al., “High-Level Expression and Efficient Assembly of Hepatitis B Surface Antigen in: The Methylotrophic Yeast, Pichia Pastoris”,Bio/Technology 5:479-485 (1987).
Dvorak et al. “Distribution of Vascular Permeability Factor (Vascular Endothelial Growth Factor) in Tumors: Concentration in Tumor Blood Vessels”,J. Exp. Med.174:1275-1278 (1991).
Ferrara and Henzel, “Pituitary Follicular Cells Secrete a Novel Heparin-Binding Growth Factor Specific For Vascular Endothelial Cells”,Biochem. Biophys. Res. Comm.161:851-858 (1988).
Fiebich et al., “Synthesis and assembly of functionally active human vascular endothelial growth factor homodimers in insect cells”,Eur. J. Biochem211:19-26 (1993).
Fiers et al., “Complete nucleotide sequence of SV50DNA”,Nature 273:113 (1978).
Freshney, “Animal Cell Culture”, ed. IRL Press (1987).
Gait, “Oligonucleotide Synthesis” ed. IRL Press (1984).
Gitay-Goren et al., “Selective Binding of VEGF121 to One of the Three Vascular Endothelial Growth Factor Receptors of Vascular Endothelial Cells”,J. Biol. Chem. 271:5519-5523 (1996).
Goeddel et al., “Direct expression inEscherichia coliof a DNA sequence coding for human growth hormone”,Nature 281:544 (1979).
Gospodarowicz et al., “Isolation and Characterization of a Vascular Endothelial Cell Mitogen produced by Pituitary-Derived Folliculo Stellate Cells”,PNAS USA,86:7311-7315 (1989).
Goto et al., “Synergistic Effects of Vascular Endothelial Growth Factor and Basic Fibroblast Growth factor on the Proliferation and Cord Formation of Bovine Capillary Endothelial Cells within Collagen Gels”,Lab. Invest. 69:508-517 (1993).
Graham et al, “Characteristics of Human Cell Line Transformed by DNA from Human Adenovirus Type 5”,J. Gen. Virol. 36:59 (1977).
Hinnen, et al., “Transformation of yeast”,Proc. Natl. Acad. Sci. USA 75:1929-1933 (1978).
Hitzeman et al., “Isolation and Characterization of the Yeast 3-Phosphoglycerokinase Gene (PGK) by an immunological Screening Technique”,J. Biol. Chem. 255:2073 (1980).
Holland et al., “Isolation and Identification of Yeast Messenger Ribonucleic Acids Coding for Enolase, Glyceraldehyde-3-Phosphate Dehydrogenase, and Phosphoglycerate Kinase”,Biochemistry,17:4900 (1978).
Houck et al., Dual regulation of vascular endothelial growth factor bioavailablity by genetic and proteolytic mechanisms,J. Biol. Chem.,267:26031-26037 (1992).
Houck et al., “The vascular endothelial growth family: identification of a fourth molecular species and characterization of alternative splicing of RNA”,Mol. Endo. 5:1806-1814 (1991).
Keck et al., “Disulfide Structure of the Heparin Binding Domain in Vascular Endothelial Growth Factor: Characterization of Posttranslational Modifications in VEGF”,Archiv. Biochem. Biophys.344:103-113 (1997).
Keck et al., “Vascular permeability factor, and endothelial cell mitogen related to PDGF.”;Science246:1309-1312 (1989).
Kelly and Hynes, “Transformation of Aspergillus niger by the amdS gene of Aspergillus nidulans”,EMBO J. 4:475-479 (1985).
Kendall and Thomas. “Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor”,PNAS USA90:10705-10709 (1993).
Keyt et al., “The carboxyl-terminal domain of vascular endothelial growth factor is critical for its mitogenic potency”,J. Biol. Chem.

Affiliated with

Also associated with

Rating

Vascular endothelial growth factor variants does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Vascular endothelial growth factor variants, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vascular endothelial growth factor variants will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3389419